<DOC>
	<DOCNO>NCT02053909</DOCNO>
	<brief_summary>Saphenous vein graft disease remain unresolved medical problem . Many vein graft occlude first year bypass surgery , lead adverse cardiovascular outcome , include recurrent angina , myocardial infarction , need repeat coronary intervention . While aspirin standard antiplatelet treatment CABG surgery , 10-20 % vein graft continue occlude despite contemporary secondary preventative therapy . Compared aspirin antiplatelet therapy like clopidogrel , ticagrelor treatment lead pronounced platelet inhibition , may substantially improve graft patency follow CABG compare aspirin . No data yet collect regard impact ticagrelor saphenous vein graft patency follow CABG . In context , investigator seek compare vein graft patency patient randomize receive aspirin therapy , current standard care , ticagrelor treatment , start early postoperative period , continue 2 year CABG .</brief_summary>
	<brief_title>Ticagrelor Antiplatelet Therapy Reduce Graft Events Thrombosis</brief_title>
	<detailed_description>This clinical trial randomize double-blind study focus ticagrelor antiplatelet therapy mean improve vein graft patency CABG . Patients eligible receive least 1 vein bypass graft time surgery . Patients randomize receive either aspirin 81 mg bid ticagrelor 90 mg bid . The aspirin ticagrelor medication prepare blinded capsule . Patients recover surgery eligible study randomization within first 5 postoperative day . Treatment continue 1 year , time patient undergo CT coronary angiogram ass graft patency . Patients invited continue participate trial 1 year , repeat CT coronary angiogram perform 2 year postoperative time-point .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Female and/or male patient age 1890 year 3 . Patients undergoing firsttime CABG least 1 saphenous vein graft , irrespective concurrent valve surgery 1 . Inability provide inform consent 2 . Pregnancy seek pregnancy 3 . Patients undergo redoCABG 4 . Serum creatinine &gt; 1.8 mg/dL ( need contrast CT coronary angiogram ) 5 . Hypersensitivity allergy aspirin ticagrelor 6 . Anticipated need postoperative anticoagulation coumadin , dabigatran rivaroxaban ( mechanical valve , chronic atrial fibrillation , DVT/PE ) 7 . History gastrointestinal hemorrhage 8 . Active pathological bleeding 9 . History intracranial hemorrhage 10 . Severe hepatic impairment 11 . Current anticipate use strong CYP3A4 inhibitor ( e.g . ketoconazole , clarithromycin , nefazadone , ritonavir , atazanavir )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Saphenous vein graft disease</keyword>
	<keyword>Coronary artery bypass graft surgery</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Secondary prevention</keyword>
	<keyword>Graft patency</keyword>
</DOC>